SCHEMBL6855600

SCHEMBL6855600

CCCC[C@](C)(CC(=O)O)C(=O)O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 5/20 0.62
CYP2D6 P10635 1/20 0.62
CYP2C19 P33261 1/20 0.62
HIF1A Q16665 1/20 0.62
TDP1 Q9NUW8 3/20 0.45
FFAR1 O14842 2/20 0.45
CPT2 P23786 1/20 0.45
HMGCR P04035 1/20 0.41
CHRM1 P11229 1/20 0.41
TBXA2R P21731 1/20 0.41
ADRA1A P35348 1/20 0.41
HSPD1 P10809 1/20 0.40
BLM P54132 1/20 0.40
HSPE1 P61604 1/20 0.40
AKR1B1 P15121 1/20 0.39
PPARG P37231 6/20 0.38
PPARD Q03181 6/20 0.38
PPARA Q07869 6/20 0.38
GPR84 Q9NQS5 5/20 0.38
HDAC11 Q96DB2 5/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2138191 1.00 TSHR (0.62) TSHRCYP2D6CYP2C19HIF1ATDP1
SCHEMBL6861770 0.94 TSHR (0.60) TSHRCYP2D6CYP2C19HIF1ATDP1
SCHEMBL18114142 0.94 TSHR (0.60) TSHRCYP2D6CYP2C19HIF1ATDP1
SCHEMBL6756932 0.92 TSHR (0.58) TSHRCYP2D6CYP2C19HIF1ATDP1
SCHEMBL6758048 0.92 TSHR (0.58) TSHRCYP2D6CYP2C19HIF1ATDP1
SCHEMBL8528310 0.92 TSHR (0.58) TSHRCYP2D6CYP2C19HIF1ATDP1
SCHEMBL13861278 0.92 TSHR (0.58) TSHRCYP2D6CYP2C19HIF1ATDP1
SCHEMBL6755326 0.92 TSHR (0.58) TSHRCYP2D6CYP2C19HIF1ATDP1
SCHEMBL2233437 0.86 CYP2C19 (0.68) TSHRCYP2D6CYP2C19HIF1ATDP1
SCHEMBL2201929 0.86 TSHR (0.46) TSHRCYP2D6CYP2C19HIF1ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6797820-B2 HYDROXAMATE DERIVATIVES THAT INHIBIT PEPTIDYL DEFORMYLASE (PDF), ANTIMICROBIALS AND ANTIBIOTICS VICURON PHARMACEUTICALS INC. 2004-09-28 US disclosed
EP-1237862-A1 SUCCINATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE AND PREPARATION Versicor, Inc. (US) 2002-09-11 EP disclosed
US-20020115863-A1 Novel succinate compounds, compositions and methods of use and preparation VICURON HOLDINGS LLC 2002-08-22 US disclosed
WO-2001044179-A1 NOVEL SUCCINATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE AND PREPARATION VERSICOR, INC. (US) 2001-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020115863-A1 Novel succinate compounds, compositions and methods of use and preparation PDF, MMP2, SDHA TSHR 4589/4885CYP2D6 862/4885CYP2C19 888/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.